The field of diabetes treatment continues to experience a surge in innovation with the emergence of novel GLP-1 receptor agonists. Among these, retatrutide and trizepatide stand out as potential game-changers. These of medications demonstrate unique pharmacological properties that offer promising therapeutic benefits for individuals with type 2 dia

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are of